Aker Biomarine AS
Aker BioMarine ASA, a biotech innovator, develops and supplies krill-derived products for consumer health and wellness worldwide. It operates through three segments: Human Health Ingredients (HHI), Consumer Health Products, and Emerging Business. The Human Health Ingredients segment sells B2B krill oil supplements for humans under the Superba Krill brand; supplements for brain health under the LY… Read more
Aker Biomarine AS (AKBM) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.046x
Based on the latest financial reports, Aker Biomarine AS (AKBM) has a cash flow conversion efficiency ratio of -0.046x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr-6.90 Million) by net assets (Nkr149.50 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Aker Biomarine AS - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Aker Biomarine AS's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Aker Biomarine AS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aker Biomarine AS ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Investcorp Europe Acquisition I Corp
NASDAQ:IVCB
|
0.151x |
|
Jiangsu GDK Biotechnology Co Ltd
SHG:688670
|
N/A |
|
VAXART INC. DL-10
F:NB11
|
N/A |
|
Velocity Financial Llc
NYSE:VEL
|
0.018x |
|
FENIX Resources Ltd
AU:FEX
|
0.332x |
|
IVF Hartmann Holding AG
SW:VBSN
|
0.014x |
|
Mammoth Energy Services Inc
NASDAQ:TUSK
|
0.003x |
|
VERSES AI Inc.
OTCQX:VRSSF
|
0.359x |
Annual Cash Flow Conversion Efficiency for Aker Biomarine AS (2016–2024)
The table below shows the annual cash flow conversion efficiency of Aker Biomarine AS from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Nkr173.90 Million | Nkr12.20 Million | 0.070x | -45.76% |
| 2023-12-31 | Nkr366.50 Million | Nkr47.40 Million | 0.129x | +224.36% |
| 2022-12-31 | Nkr378.70 Million | Nkr15.10 Million | 0.040x | +1925.77% |
| 2021-12-31 | Nkr370.37 Million | Nkr729.00K | 0.002x | +101.44% |
| 2020-12-31 | Nkr373.17 Million | Nkr-51.04 Million | -0.137x | -271.77% |
| 2019-12-31 | Nkr154.55 Million | Nkr12.31 Million | 0.080x | +80.36% |
| 2018-12-31 | Nkr178.81 Million | Nkr7.89 Million | 0.044x | -71.46% |
| 2017-12-31 | Nkr59.30 Million | Nkr9.17 Million | 0.155x | -45.15% |
| 2016-12-31 | Nkr74.03 Million | Nkr20.88 Million | 0.282x | -- |